Tech Session II: Nanomedicine and Nanoscale Delivery (Focus: Imaging)
uSPIO-5D3-DM1 Nano-conjugates as Optical-MRI Theranostics for PSMA-Positive Prostate Cancer Therapy
Tuesday, July 15, 2025
3:05 PM - 3:16 PM EDT
Location: 121 B/C
Introduction: Prostate cancer (PC) is one of the most widely diagnosed malignancies among men worldwide.[1-2] Almost all PCs eventually become insensitive to ADT and progress rapidly to the incurable metastatic castration-resistant PC (mCRPC).[3] Prostate-specific membrane antigen (PSMA) is overexpressed in most PCs (>95%).[4] The ultrasmall superparamagnetic iron oxide (uSPIO) nanoparticle-based image-guided and targeted drug delivery systems combine active and passive targeting properties and diagnosis and therapy. This strategy enhances therapeutic efficacy with minimal systemic toxicities.
Learning Objectives:
At the completion of this activity, participants will know
Upon completion, participant will be able to learn a novel MRI-theranostic drug delivery strategy.
Upon completion, participant will be able to learn novel in vitro and in vivo imaging techniques.
Upon completion, participant will be able to develop new collaborations.
Sharmane Surasinghe – AE UG Senior, The Johns Hopkins University; Zora Nováková – Research Faculty, Institute of Biotechnology of the Czech Academy of Sciences; Cyril Bařinka – Research Faculty, Institute of Biotechnology of the Czech Academy of Sciences; Dmitri Artemov – Professor, The Johns Hopkins School of Medicine
